Multiplicom, a Niel, Belgium-based molecular diagnostics startup, has raised €2.0m in its Series A funding round.
Backers include Gimv, Gimv managed Biotechfonds Vlaanderen, VIB and University of Antwerp. Gimv and Gimv managed funds invest €1.5m while VIB and UA together invest the balance of €0.5m.
The company intends to use the funds for the development of innovative diagnostic tests, CE-marking of diagnostic assays, and to build a sales network in the European Union.
Multiplicom, a spin out of the Jurgen Del-Favero lab of the VIB Department of Molecular Genetics at the University of Antwerp (UA), where its core Multiplexer™ technology was developed, is specialized in the development, manufacturing and commercialization of innovative molecular genetic tests.
These tests allow:
– to determine whether an individual has an increased genetic risk to develop a disease,
– early detection of congenital genetic defect, or
– to identify the most appropriate therapy for patients.
Led by CEO Dirk Pollet, Multiplicom initially focuses on direct sales in Western European countries in combination with new distributors in other countries.
FinSMEs
29/04/2011